抗MDA5自身抗体相关幼年皮肌炎在北美构成独特表型
该研究回顾性分析北美注册队列中35例抗MDA5抗体阳性幼年特发性炎性肌病(JIIM)患者,发现其占JIIM的7.7%,表现为诊断年龄较大、肌酸激酶和醛缩酶水平较低,更常见体重下降、腺病、关节炎和间质性肺病(ILD),与抗TIF1、抗NXP2及抗体阴性患者不同,且与抗合成酶抗体阳性者相比ILD和技工手更少、诊断季节不同。抗MDA5患者用药更少、激素疗程更短,缓解率高于抗合成酶组,多变量分析中体重下降和关节炎/关节痛与抗MDA5阳性最强相关。
要点
- 抗MDA5抗体见于7.7%的JIIM患者,构成独立临床亚型。
- 突出表现为关节炎、体重下降、腺病和ILD,但肌炎较轻。
- 与抗合成酶组相比ILD和技工手更少,激素疗程更短、缓解率更高。
核心结论
- 抗MDA5抗体相关JIIM是独立亚型,以关节炎、体重下降、腺病和较轻肌炎为特征,并伴ILD。
研究设计与样本
- 回顾性分析北美注册队列中35例抗MDA5抗体阳性JIIM患者,并与其它肌炎特异性抗体组比较。
主要发现
- 抗MDA5抗体占JIIM的35/453(7.7%),与诊断年龄较大及较低血清肌酸激酶和醛缩酶水平相关。
- 抗MDA5组较抗TIF1、抗NXP2及抗体阴性组更常见体重下降、腺病、关节炎和ILD,较少跌倒。
- 抗MDA5组较抗合成酶组诊断季节不同,技工手和ILD更少。
- 抗MDA5组用药少于抗TIF1组,激素疗程短于抗TIF1和抗NXP2组。
- 抗MDA5组缓解率高于抗合成酶组;多变量分析中体重下降、关节炎和关节痛与抗MDA5阳性最强相关。
关键数值与推荐
- 抗MDA5抗体阳性率为7.7%(35/453例JIIM患者)。
- 抗MDA5组激素疗程较抗TIF1和抗NXP2组更短,缓解率高于抗合成酶组。
临床怎么用
- 对JIIM患者应检测抗MDA5抗体以识别以关节炎、体重下降、腺病和ILD为突出表现且肌炎较轻的亚型。
- 抗MDA5阳性JIIM患者可考虑更短激素疗程,并关注ILD评估。
局限性
- 回顾性研究设计,样本量有限(35例抗MDA5阳性患者)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Myositis-specific autoantibodies have defined distinct phenotypes of patients with juvenile myositis (JIIM). We assessed the frequency and clinical significance of anti-melanoma differentiation-associated gene 5 (MDA5) autoantibody-associated JIIM in a North American registry. METHODS: Retrospective examination of the characteristics of 35 JIIM patients with anti-MDA5 autoantibodies was performed, and differences from other myositis-specific autoantibody groups were evaluated. RESULTS: Anti-MDA5 autoantibodies were present in 35/453 (7.7%) of JIIM patients and associated with older age at diagnosis, and lower serum creatine kinase and aldolase levels. Patients with anti-MDA5 autoantibodies had more frequent weight loss, adenopathy, arthritis, interstitial lung disease (ILD), and less frequent falling compared with anti-transcriptional intermediary factor 1 (TIF1), anti-nuclear matrix protein 2 (NXP2) and myositis-specific autoantibody/myositis-associated autoantibody-negative patients. They had a different season of diagnosis and less frequent mechanic's hands and ILD compared with those with anti-synthetase autoantibodies. Anti-MDA5 patients received fewer medications compared with anti-TIF1, and corticosteroid treatment was shorter compared with anti-TIF1 and anti-nuclear matrix protein 2 autoantibody groups. The frequency of remission was higher in anti-MDA5 than anti-synthetase autoantibody-positive JIIM. In multivariable analyses, weight loss, arthritis and arthralgia were most strongly associated with anti-MDA5 autoantibody-positive JIIM. CONCLUSION: Anti-MDA5 JIIM is a distinct subset, with frequent arthritis, weight loss, adenopathy and less severe myositis, and is also associated with ILD. Anti-MDA5 is distinguished from anti-synthetase autoantibody-positive JIIM by less frequent ILD, lower creatine kinase levels and differing seasons of diagnosis. Anti-MDA5 has comparable outcomes, but with the ability to discontinue steroids more rapidly and less frequent flares compared with anti-TIF1 autoantibodies, and more frequent remission compared with anti-synthetase JIIM patients.
引用
- Mamyrova G, Kishi T, Shi M, et al. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America. Rheumatology (Oxford). 2021. PMID: 33140079. doi:10.1093/rheumatology/keaa429
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。